UBE2I and atherosclerosis: MiR-30e and lincRNA-p21 act as potential targets for the treatment of atherosclerosis by inhibiting human VSMC proliferation and migration, respectively, via the miR-30e/Ube2i/IκBα/NFκB and lincRNA-p21/MDM2/p53 axes (83, 84).